Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019)

Historic Preferred Stock Liabilities for 4D Molecular Therapeutics (FDMT) over the last 1 years, with Q4 2019 value amounting to $103.0 million.

  • 4D Molecular Therapeutics' Preferred Stock Liabilities changed N/A to $103.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $103.0 million, marking a year-over-year change of. This contributed to the annual value of $103.0 million for FY2019, which is N/A changed from last year.
  • 4D Molecular Therapeutics' Preferred Stock Liabilities amounted to $103.0 million in Q4 2019.
  • In the past 5 years, 4D Molecular Therapeutics' Preferred Stock Liabilities ranged from a high of $103.0 million in Q4 2019 and a low of $103.0 million during Q4 2019